Janux Therapeutics (JANX) Accounts Payables (2020 - 2026)

Janux Therapeutics (JANX) has 7 years of Accounts Payables data on file, last reported at $3.4 million in Q1 2026.

• Accounts Payables for Q1 2026 came in at $3.4 million, up 43.6% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.4 million (up 43.6% YoY), and the FY2025 annual result was $5.0 million, up 23.47% from the prior year.
• Accounts Payables eased to $3.4 million in Q1 2026 per JANX's latest filing, from $5.0 million in the prior quarter.
• Over five years, Accounts Payables peaked at $5.0 million in Q4 2025 and troughed at $1.3 million in Q2 2024.
• A 5-year average of $2.7 million and a median of $2.5 million in 2024 frame the typical range for Accounts Payables.
• The sharpest annual moves came in 2022 and 2023: Accounts Payables soared 747.46% in 2022, then slumped 36.33% in 2023.
• A 5-year view of Accounts Payables shows it stood at $2.2 million in 2022, then advanced by 12.27% to $2.4 million in 2023, then surged by 66.09% to $4.0 million in 2024, then advanced by 23.47% to $5.0 million in 2025, then sank by 32.09% to $3.4 million in 2026.
• Business Quant data shows JANX's Accounts Payables at $3.4 million in Q1 2026, $5.0 million in Q4 2025, and $3.4 million in Q3 2025.